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Bioactive Pyrrole Alkaloids isolated from the Red Sea  
Marine Sponge Stylissa carteri 
 
Abstract: Fifteen pyrrole alkaloids were isolated from the Red Sea marine sponge 
Stylissa carteri and investigated for their biological activities. Four of them were 
dibrominated [(+) dibromophakelline, Z-3-bromohymenialdisine, (±) ageliferin and 
3,4-dibromo-1H-pyrrole-2-carbamide], nine compounds were monobrominated [(-) 
clathramide C, agelongine, (+) manzacidin A, (-) 3-bromomanzacidin D, Z-
spongiacidin D, Z-hymenialdisine, 2-debromostevensine, 2-bromoaldisine and 4-
bromo-1H-pyrrole-2-carbamide)] and finally, two compounds were non-brominated 
derivatives viz., [(E-debromohymenialdisine and aldisine)]. The structure elucidation 
of the isolated compounds were based on 1D and 2D NMR spectroscopic and MS 
studies, as well as by comparison with the literature. In-vitro, Z-spongiacidin D 
exhibited a moderate activity on (ARK5, CDK2-CycA, CDK4/CycD1, VEGFR-2, SAK 
and PDGFR) protein kinases. Furthermore, Z-hymenialdisine displayed a moderate 
effect on (ARK5, VEGFR-2, SAK and PDGFR) protein kinases. While, (-) 
clathramide C showed a moderate activity on AURORA-A. Moreover, Z-3-
bromohymenialdisine showed distinct inhibition of (AURORA-A, CDK4/CycD1, FAK, 
VEGFR-2, SAK and PDGFR) protein kinases. While, others showed only a marginal 
inhibitory activity e.g. agelongine and (+) manzacidin A. The inhibition of these 
prominent protein kinases suggests a potential use of these compounds as cytostatic 
drugs. In L5178Y cell lines, the most effective secondary metabolites were (+) 
dibromophakelline and Z-3-bromohymenialdisine. Finally, Z-hymenialdisine, Z-3-
bromohymenialdisine and (±) ageliferin exhibited the highest cytotoxic activity on 
HCT116 cell lines.  
 
Keywords: Stylissa carteri; Sponge; pyrrole alkaloids; protein kinase; cytotoxicity. 
 
1 Introduction 
 
Marine sponges (Phylum: Porifera) have attracted substantial research interest 
because of their ecological importance and their production of a wide range of 
bioactive compounds for pharmacological use [1,2]. The Red Sea is a unique and 
largely unexplored marine ecosystem, where its sponges have been studied during 
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the past two decades for their natural products and bioactive constituents, as well as 
for their ecological importance [3].  
Stylissa carteri is one of the interesting sponges from the Red Sea. Several 
bromopyrrole alkaloids were isolated from it. A review demonstrated that these 
alkaloids showed promising biological activities, as hymenialdisine, first isolated in 
1980 from the marine sponges of the genera Hymeniacidon, Acanthella, Axinella and 
Pseudaxinyssa. S. carteri is a well-known protein kinase inhibitor [4].  
This sponge potently inhibited glycogen synthase kinase 3ȕ, cyclin-dependent 
kinase 2 and cyclin-dependent kinase 5, whereas dibromocantharelline (another 
brominated sponge component) only displayed a significant inhibitory effect toward 
glycogen synthase kinase 3ȕ with IC50 ȝPRO[5].  
Moreover, 10-E-hymenialdisine and 10-Z-hymenialdisine showed a potent 
inhibition of RAF/MEK-1/MAPK cascade with IC50 values of 3 and 6 nM, respectively 
[6]. Both of these alkaloids also inhibited the growth of human LoVo tumor cells. 
Hymenialdisine competed with ATP for binding to distinct kinases, like cyclin-
dependent kinases, glycogen synthase kinase-3ȕ and casein kinase 1 [7]. 
Hymenialdisine inhibited interleukin-8 production in U937 cells by inhibition of 
nuclear factor-kappaB [8]. 
Furthermore, spongiacidin C (a pyrrole alkaloid was isolated from the marine 
sponge Stylissa massa) inhibited USP7, a deubiquitylating enzyme hydrolyzing the 
isopeptide bond at the C-terminus of ubiquitin. This potential cancer target was 
inhibited with IC50 ȝ0 [9].  
Finally, the brominated alkaloids viz., debromohymenialdisine, hymenialdisine 
and 3-bromohymenialdisine of Axinella carteri exhibited cytotoxic activities on 
L5178Y mouse lymphoma cell lines. They displayed ED50 values; 1.8, 3.9 and 3.9 
µg/mL, respectively [10].  
Therefore, this study aimed the investigation of the biological activities of the 
isolated alkaloids from S. carteri viz., in-vitro protein kinases activities and cytotoxic 
effects using two different cell lines. 
 
2 Material and methods 
 
2.1 Animal material 
 
4 
 
The sponge Stylissa carteri (syn. Axinella carteri) [Phylum: Porifera, Class: 
Demospongiae, Order: Halichondrida, Family: Dictyonellidae, Genus: Stylissa, 
Species: S. carteri] was collected in June 2006 at a depth of 12 m, from the Red 
Sea, Hurghada, Egypt. It was identified by Prof. van Soest, RWM, (Zoological 
Museum; Amsterdam, The Netherlands) for the identification of the sponge. It is a 
reddish orange flabellate sponge. The sponge material was immersed in ethanol 
immediately after collection. A voucher specimen was kept in ethanol under 
registration number ZMAPOR 19838 at the Zoological Museum, Amsterdam, The 
Netherlands. 
 
2.2 Chromatography and spectroscopic analyses 
 
2.2.1 Vacuum liquid chromatography (VLC) 
 
It was performed on silica gel 60 (0.040-0.063 mm; Merck, Darmstadt, Germany). n-
Hexane, CH2Cl2 and MeOH were used as mobile phases. Column chromatography 
was carried out on silica gel 60, sephadex LH-20 and reversed phase LiChroprep 
RP-18 (25-ȝP 0HUFN. For silica gel column chromatography, varying ratios of 
CH2Cl2/MeOH were used as mobile phases. For sephadex LH-20 column 
chromatography, the mobile phase was 100% MeOH. For RP-18 column 
chromatography, two mobile phases were used; either acetonitrile or acetonitrile/H2O 
(3:7). TLC analysis was carried out using aluminum sheet precoated with silica gel 
60 F254 (Merck, Darmstadt, Germany). The compounds were detected by their UV 
absorbance at 254 and 366 nm. 
 
2.2.2 Analytical HPLC analysis 
 
The samples were injected into a HPLC system equipped with a photodiode array 
detector (Dionex, Munich, Germany). The routine detection was at 235, 254, 280 and 
340 nm. The separation column (125 X 4 mm ID) was prefilled with Eurosphere 100-
5 C-18, 5 ȝm (Knauer, Berlin, Germany) and flow rate 1 mL/min. The separation was 
achieved by applying a linear gradient from 90% H2O (pH 2.0 Nanopure water using 
ortho-phosphoric acid 85% p.a., Merck) to 100% MeOH over 40 min.  
 
2.2.3 Semi-preparative HPLC 
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The separations were done on a LaChrom-Merck Hitachi HPLC machine, pump L-
7100, UV detector L-7400. The separation column (300 X 8 mm ID) was prefilled 
with Eurosphere 100-5 C-18, 5 ȝm (Knauer, Berlin, Germany), flow rate 5 mL/min, 
UV detection at 280 nm). The compounds were eluted with a solvent system of 
nanopure H2O/MeOH (gradient elution starting with a concentration of 10% MeOH 
and increasing the concentration in a linear manner within 25 min up to 60%). 
 
2.2.4 Medium Pressure Liquid Chromatography (MPLC) 
 
The separations were done on Büchi MPLC; Gradient molder with mixing chamber 
B-687, fraction collector: B-684, Column size: (ID 460 X 26 mm), was prefilled with 
reversed phase LiChroprep RP-18 (25- ȝP 0HUFN, flow rate 3 mL/min. The 
mobile phases were either H2O/MeOH (7.5:2.5) or H2O/MeOH gradient elution. 
Mass spectra (ESI-MS) were recorded on a Thermo Finnigan LCQ DECA mass 
spectrometer coupled to an Agilent 1100 HPLC system equipped with a photodiode 
array detector. HRFT-MS was recorded on a LTQ-FT-MS-Orbitrap (Thermo 
Finnigan, Bremen, Germany). Optical rotation was determined on a Perkin-Elmer-
241 MC polarimeter. 
 
2.2.5 Spectroscopic analyses 
 
1D and 2D NMR spectra were recorded at 300 °K on either a Bruker ARX-500 or 
AVANCE DMX-600 NMR spectrometer. Samples were dissolved in different 
deuterated solvents, whose choice was dependent on the solubility of each 
compound. 
 
2.3 Extraction and isolation  
 
The dried fine powder of Stylissa carteri (600 g) was extracted exhaustively with 
methanol (4x, 3 L each) and concentrated to yield (90 g) residue. The resulting 
extract was dissolved in the least amount of demineralized water and partitionated 
with EtOAc and n-BuOH, respectively. The extraction and fractionation were 
demonstrated in (Scheme 1a).  
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The n-BuOH-soluble material of S. carteri was concentrated under vacuum to 
afford 18 g. It was subjected to column chromatography on sephadex LH-20 using 
methanol as mobile phase. Four fractions were obtained (I to IV). Fraction (I, 3.05 g) 
was further subjected to reversed phase column chromatography (RP-18, 25-ȝP
Merck) using acetonitrile as a mobile phase to yield compounds 1 (6 mg). 
Furthermore, fraction (II, 3.58 g) was subjected to MPLC on reversed phase (RP-18, 
25- ȝP 0HUFN using H2O/MeOH gradient elution to give three subfractions 
(Subfr. II-1 to II-3). Compound 2 (12 mg) was precipitated in pure form from 
subfraction (Subfr. II-1). On the other hand, subfraction (Subfr. II-2, 50 mg) was 
further submitted to column chromatography on reversed phase (RP-18, 25-ȝP
Merck) using acetonitrile/H2O (3:7) as a mobile phase to give compounds 3 (5 mg) 
and 4 (2 mg), respectively. In addition to, subfraction (Subfr. II-3, 30 mg) was further 
purified on semi-preparative HPLC to obtain compound 5 (8 mg). Moreover, fraction 
(III, 4.9 g) was further subjected to MPLC using reversed phase (RP-18, 25-ȝP
Merck) and H2O/MeOH (7.5:2.5) as an isocratic elution system to yield eight 
subfractions (from Subfr. III-1 to III-8). Subfraction (Subfr. III-3, 80 mg) was further 
purified using semi-preparative HPLC to afford three compounds 6 (3 mg), 7 (2 mg) 
in addition to 8 (4 mg), respectively. On the other hand, subfraction (Subfr. III-6, 30 
mg) was submitted to further purification using semi-preparative HPLC to give 
compound 9 (5 mg). Furthermore, subfraction (Subfr. III-7, 30 mg) was subjected to 
semi-preparative HPLC to give compound 10 (7 mg). Finally, compound 11 (10 mg) 
was precipitated in pure form from subfraction (Subfr. III-8). Chromatographic 
fractionations of n-butanol fraction of S. carteri sponge were illustrated in (Scheme 
1b). 
While, the EtOAc soluble material of S. carteri was concentrated under vacuum 
to yield (12 g) residue. It was subjected to VLC on silica gel, using gradient elution 
consisting of different portions of n-Hexane/CH2Cl2 to CH2Cl2/MeOH. Elution started 
with 100% n-Hexane and the CH2Cl2 concentrations were increased gradually till 
100% CH2Cl2 and then the MeOH concentrations were increased gradually till 100% 
MeOH. Ten fractions were obtained (from I to X). Compound 12 (3 mg) was 
precipitated as a pure substance from fraction (VII). Additionally, fraction (IX, 500 
mg) was further subjected to silica gel column chromatography using CH2Cl2/MeOH 
in gradient elution manner to yield seven subfractions (from Subfr. IX-1 to IX-7). 
Subfraction (Subfr. IX-4, 110 mg) was further purified by reversed phase column 
chromatography (RP-18, 25-ȝP0HUFN using acetonitrile as a mobile phase to 
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afford three compounds; 13 (8 mg), 14 (6 mg) and 15 (2 mg), respectively. 
Chromatographic fractionations of EtOAc fraction of S. carteri sponge were shown in 
(Scheme 1c). 
 
2.4 Protein kinase assay 
 
Assays for the measurement of protein kinase activity were performed in 96-well 
FlashPlates (Perkin Elmer/NEN, Boston, MA, USA) in a 50 mL reaction volume. The 
reaction cocktail contained 20 mL assay buffer, 5 mL ATP solution (in demineralized 
water), 5 mL test compound (in 10% DMSO), 10 mL substrate and 10 mL purified 
recombinant protein kinase. The final concentration of ATP was 1 mM. The assay for 
all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 
mM Na-orthovanadate, 1.2 mM DTT, 50 mg/mL PEG20000 and 1 mM [J33P]-ATP 
(approximately 5 * 105 cpm/well).  
The following substrates were used: glycogen synthase kinase 3 (GSK3) (14-
27): AKT1 serine-threonine kinase, tetra(LRRWSLG): AURORA serine/threonine 
kinases A and B, MEK kinase 1: B-RAF-VE kinase, Histone H1: Cyclin-dependent 
kinase (CDK2/CycA), Rb-CTF: Cyclin-dependent kinase 4 CDK4/CycD1, P53-CTM 
:anti-casein kinase 2 alpha (CK2alpha1), Poly(Glu,Tyr)4:1: [epidermal growth factor 
receptor (EGFR), ephrin type B receptor 4 (EPHB4), ERBB2 receptor protein 
tyrosine kinase, focal adhesion kinase (FAK), insulin like growth factor 1 receptor 
(IGF1-R), SRC tyrosine kinase and vascular endothelial growth factor receptor 
(VEGF-R2)], Casein: Polo-like kinase PLK-1, poly(Ala, Glu, Lys, Tyr)6:2:4:1: [INS-R 
and MET] and Casein: platelet derived growth factor (PDGFR-beta). 
Autophosphorylation was measured for ARK5 serine/threonine kinase, COT kinase 
and SAK kinase.  
The assay for all enzymes contained 60 mM HEPES-NaOH (pH 7.5), 3 mM 
MgCl2, 3 mM MnCl2, 3 ȝ01D-ortKRYDQDGDWHP0'77ȝJmL PEG20000, 1 
ȝ0 >J-33P]-ATP. The reaction mixtures were incubated at 30 °C for 80 min and 
VWRSSHG ZLWK  ȝ/ % (v/v) H3PO4. The plates were aspirated and washed two 
WLPHV ZLWK  ȝ/ RI  ZY 1D&O RU  ȝ/ +2O. Incorporation of J33P was 
determined with a microplate scintillation counter (Microbeta Trilux, Wallac). All 
assays were performed with a Beckman Coulter/Sagian robotic system [11,12]. 
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2.5 Cytotoxicity test 
 
The cytotoxicity was determined by using two different cell lines: 
 
2.5.1 L5178Y cell lines  
 
They ZHUHJURZQLQ(DJOH¶VPLQLPDOHVVHQWLDOPHGLXPVXSSOHPHQWZLWKKRUVH
serum in roller tube culture. The medium contained 100 units/mL penicillin and 100 
ȝJmL streptomycin. The cells were maintained in a humidified atmosphere at 37 °C 
with 5% CO2. An aliquot of 50 µL cell suspension (3750 cells) was pipetted into each 
cavity of a 96-well microtiter plate together with 50 µL of the compounds in EMEM (3 
WR  ȝJmL) and incubated for 72 h (37 °C, 5% CO2). A solution of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was prepared at 5 
mg/mL in phosphate buffered saline (PBS; 1.5 mM KH2PO4, 6.5 mM Na2HPO4, 137 
mM NaCl, 2.7 P0.&OS+DQGIURPWKLVVROXWLRQȝ/ZDVSLSHWWHGLQWRHDFK
well. The yellow MTT penetrates the healthy living cells and in the presence of 
mitochondrial dehydrogenases, MTT is transformed to its blue formazan complex. 
After an incubation period of 3 h (37 °C, 5% CO2), the medium was centrifuged (15 
min, 20 °C, 210 xJ ZLWK  ȝ/ '062 DQG WKH FHOOV ZHUH O\VHG WR OLEHUDWH WKH
formed formazan product. After thorough mixing, the absorbance was measured at 
520 nm using a scanning microtiter-well spectrophotometer. The colour intensity is 
correlated with the number of viable cells [13,14]. All experiments were carried out in 
triplicates and repeated three times. As controls, media with 0.1% DMSO were 
included in the experiments.  
 
2.5.2 HCT116 cell lines  
 
They were evaluated according to Mosmann [14] with slight modifications [15]. 
 
2.6 Statistical analyses 
 
All data are given as mean +/- SD. The significance of changes in the test responses 
was assessed using analysis of variance (GraphPad Prism: version 5.0, La Jolla, 
USA). Statistical significance was assessed by unpaired Student's (t) test, 
differences were considered to be significant at p DQGLQGLFDWHGDV³´ 
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3 Results 
 
3.1 Isolation of the pyrrole alkaloids 
 
From the Red Sea sponge S. carteri, fifteen compounds were isolated. All isolated 
compounds were identified by comparison with different techniques of spectroscopy 
(UV, MS and NMR) data with those in the literature: (-) clathramide C (1) [16], 
agelongine (2) [17], (+) manzacidin A (3) [18], (-) 3-bromomanzacidin D (syn. N-
methylmanzacidin C) (4) [19], (+) dibromophakelline (5) [20], E-
debromohymenialdisine (6) [21], Z-spongiacidin D (syn. axinohydantoin) (7) [22], Z-
hymenialdisine (8) [21], Z-3-bromohymenialdisine (syn. Spongiacidin A) (9) [21], 2-
debromostevensine (syn. 2-debromoodiline) (10) [21], (±) ageliferin (11) [23], 3,4-
dibromo-1H-pyrrole-2-carbamide (12) [24], aldisine (13) [25], 2-bromoaldisine (14) 
[25] and 4-bromo-1H-pyrrole-2-carbamide (15) [26-28]. The chemical structures are 
shown in (Figure 1).  
 
3.1.1 (-) Clathramide C (1) [16] 
Yellow residue. 
890H2+Ȝmax: 221.5 and 277.2 nm.  
      -7.0o (c 0.11, MeOH).  
1H-NMR (500 MHz, CD3OD): 7.03 (1H, br s, H-2), 6.84 (1H, br s, H-4), 4.04 (1H, m, 
H-8), 2.28 (2H, m, H-9), 4.57 (1H, d, J=11.7 Hz, H-11a), 4.35 (1H, d, J=11.7 Hz, H-
11b), 7.99 (1H, br s, H-13) and 1.46 (3H, s, H-15). 13C-NMR (125 MHz, CD3OD): 
160.4 (C, C-6), 154.0 (CH, C-13), 125.6 (CH, C-2), 123.4 (C, C-5), 118.3 (CH, C-4), 
98.2 (C, C-3), 67.2 (CH2, C-11), 58.3 (C, C-10), 52.4 (CH, C-8), 32.1 (CH2, C-9), 
24.2 (CH3, C-15) and C-16 not detected. ESI-MS: m/z 342 and 344 [M, 1:1] for 
C12H1579BrN4O3. 
 
3.1.2 Agelongine (2) [17] 
Yellow residue. 
890H2+Ȝmax: 217.1, 234.0 and 271.8 nm. 
1H-NMR (500 MHz, CD3OD): 6.90 (1H, br s, H-2), 6.80 (1H, br s, H-4), 4.75 (2H, t, 
J=4.8 Hz, H-8), 5.03 (2H, t, J=4.5 Hz, H-9), 9.38 (1H, s, H-11), 8.97 (1H, d, J=8.0 Hz, 
H-13), 8.09 (1H, t, J=7.7 Hz, H-14) and 9.01 (1H, d, J=6.0 Hz, H-15). 13C-NMR (125 
MHz, CD3OD): 166.7 (C, C-16), 160.4 (C, C-6), 147.4 (CH, C-11), 147.0 (CH, C-13), 
> @20DD
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146.5 (CH, C-15), 140.2 (C, C-12), 128.8 (CH, C-14), 125.6 (CH, C-2), 123.0 (C, C-
5), 118.5 (CH, C-4), 98.2 (C, C-3), 63.6 (CH2, C-8) and 61.8 (CH2, C-9). ESI-MS: m/z 
340 and 342 [M, 1:1] for C13H1379BrN2O4. 
 
3.1.3 (+) Manzacidin A (3) [18] 
Yellow residue. 
890H2+Ȝmax: 203.8 and 275.8 nm. 
      +11.6 o (c 0.67, MeOH).  
1H-NMR (600 MHz, DMSO-d6): 12.56 (1H, br s, -NH-1), 7.22 (1H, br s, H-2), 6.90 
(1H, br s, H-4), 4.27 (1H, d, J=11.0 Hz, H-8a), 4.21 (1H, d, J=11.0 Hz, H-8b), 2.12 
(1H, dd, J=5.4, 14.2 Hz, H-10eq), 1.80 (1H, dd, J=10.7, 13.6 Hz, H-10ax), 4.36 (1H, 
d, J=11.0 Hz, H-11), 7.90 (1H, s, H-13), 9.55 (1H, br s, H-14) and 1.28 (3H, s, H-15). 
13C-NMR (150 MHz, CD3OD): 174.2 (C, C-16), 160.4 (C, C-6), 151.3 (CH, C-13), 
125.3 (CH, C-2), 123.4 (C, C-5), 118.3 (CH, C-4), 98.1 (C, C-3), 69.0 (CH2, C-8), 
54.0 (C, C-9), 51.6 (CH, C-11), 32.1 (CH2, C-10) and 24.2 (CH3, C-15). ESI-MS: m/z 
343 and 345 [M, 1:1] for C12H1479BrN3O4. 
 
3.1.4 (-) 3-Bromomanzacidin D (N-Methylmanzacidin C) (4) [19] 
Yellow residue. 
UV (0H2+Ȝmax: 218.1 and 276.3 nm. 
           
-3.4o (c 0.3, CHCl3). 
1H-NMR (600 MHz, CD3OD): 7.04 (1H, d, J= 1.5 Hz, H-2), 6.85 (1H, d, J= 1.5 Hz, H-
4), 4.58 (1H, d, J= 11.4 Hz, H-8a), 4.30 (1H, d, J= 12.3 Hz, H-8b), 2.63 (1H, dd, J= 
5.7, 11.7 Hz, H-10eq), 1.94 (1H, dd, J= 11.4, 11.4 Hz, H-10ax), 4.13 (1H,dd, J= 5.0, 
11.0 Hz, H-11), 8.00 (1H, br.s, H-13), 3.23 (3H, s, H-15) and 1.47 (3H, s, H-17). 13C-
NMR (150 MHz, CD3OD): 13C-NMR (150 MHz, CD3OD): 174.3 (C, C-16), 160.7 (C, 
C-6), 154.0 (CH, C-13), 125.6 (CH, C-2), 123.4 (C, C-5), 118.5 (CH, C-4), 98.3 (C, 
C-3), 67.1 (CH2, C-8), 58.3 (C, C-9), 52.4 (CH, C-11), 35.1 (CH2, C-10), 36.9 (CH3, 
C-15) and 21.4 (CH3, C-17). ESI-MS: m/z 357 and 359 [M, 1:1] for C13H1679BrN3O4. 
 
3.1.5 (+) Dibromophakelline (5) [20] 
Brown residue. 
UV (MeOH) Ȝmax: 237.1 and 289.4 nm. 
      +3.0o (c 0.11, MeOH). 
> @20DD
> @20DD
> @20DD
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1H-NMR (500 MHz, CD3OD): 7.01 (1H, s, H-3), 6.23 (1H, s, H-6), 2.42 (1H, m, H-
11a), 2.43 (1H, m, H-11b), 2.16 (1H, m, H-12a), 2.19 (1H, m, H-12b), 3.63 (1H, m, H-
13a) and 3.84 (1H, m, H-13b). 13C-NMR (125 MHz, DMSO-d6): 156.3 (C, C-15), 
153.7 (C, C-8), 125.0 (C, C-4), 114.8 (CH, C-3), 106.1 (C, C-5), 102.0 (C, C-2), 82.4 
(C, C-10), 68.2 (CH, C-6), 44.7 (CH2, C-13), 38.5 (CH2, C-11) and 19.0 (CH2, C-12). 
ESI-MS: m/z 387, 389 and 391 [M, 1:2:1] for C11H1179Br2N5O. 
 
3.1.6 E-Debromohymenialdisine (6) [21] 
Yellow amorphous powder. 
890H2+Ȝmax: 212.0, 240.5 and 362.1 nm. 
1H-NMR (500 MHz, DMSO-d6): 11.37 (1H, br s, -NH-1), 7.06 (1H,br s, H-2), 6.78 
(1H, d, J=2.5 Hz, H-3), 7.76 (1H, br s, -NH-7), 3.19 (2H, t, J=5.1 Hz, H-8), (H-9) 
under solvent peak from 1H-1H COSY, 9.52 (2H, br s, -NH2-14) and 10.40 (1H, br s, -
NH-15). ESI-MS: m/z 245 (M) for C11H11N5O2. 
 
3.1.7 Z-Spongiacidin D (syn. Axinohydantoin) (7) [22] 
Yellow amorphous powder. 
UV (MeOH) Ȝmax: 241.2, 259.8 and 360.1 nm. 
1H-NMR (500 MHz, DMSO-d6): 12.16 (1H, br s, -NH-1), 7.00 (1H, s, H-3), 7.84 (1H, 
t, J=4.6 Hz, -NH-7), 3.19 (2H, br s, H-8), 3.19 (2H, br s, H-9), 9.58 (1H, br s, -NH-13) 
and 10.55 (1H, br s, -NH-15). ESI-MS: m/z 324 and 326 [M, 1:1] for C11H979BrN4O3. 
 
3.1.8 Z-Hymenialdisine (8) [21] 
Yellow amorphous powder. 
UV (0H2+Ȝmax: 210.1, 262.1 and 354.7 nm. 
1H-NMR (500 MHz, DMSO-d6): 12.17 (1H, br s, -NH-1), 6.77 (1H, s, H-3), 7.93 (1H, t, 
J=4.3 Hz, -NH-7), 3.17 (2H, br s, H-8), 3.17 (2H, br s, H-9), 9.10 (2H, br s, -NH2-14) 
and 10.56 (1H, br s, -NH-15). ESI-MS: m/z 323 and 325 [M, 1:1] for C11H1079BrN5O2. 
 
3.1.9 Z-3-Bromohymenialdisine (syn. Spongiacidin-A) (9) [21] 
Yellow amorphous powder. 
890H2+Ȝmax: 201.8, 271.6 and 330.1 nm. 
1H-NMR (500 MHz, DMSO-d6): 13.06 (1H, br s, -NH-1), 7.87 (1H, br s, -NH-7), 3.18 
(2H, br s, H-8), 3.18 (2H, br s, H-9), 8.81 (2H, br s, -NH2-14) and 10.38 (1H, br s, -
NH-15). ESI-MS: m/z 401, 403 and 405 [M, 1:2:1] for C11H979Br2N5O2. 
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3.1.10 2-Debromostevensine (syn. 2-Debromoodiline) (10) [21] 
Brown residue. 
1H-NMR (500 MHz, DMSO-d6): 11.91 (1H, br s, -NH-1), 7.00 (1H, s, H-2), 8.50 (1H, 
t, J=5.7 Hz, -NH-7), 3.93 (2H, t, J=5.1 Hz, H-8), 6.16 (1H, t, J=4.8 Hz, H-9), 12.69 
(1H, br s, -NH-12), 7.45 (2H, br s, -NH2-13), 11.91 (1H, br s, -NH-14) and 6.87 (1H, 
s, H-15). ESI-MS: m/z 307 and 309 [M, 1:1] for C11H1079BrN5O. 
 
3.1.11 (±) Ageliferin (11) [23] 
Brown residue. 
       0o (c 0.11, MeOH) 
890H2+Ȝmax: 228.7 and 271.9 nm. 
1H-NMR (500 MHz, CD3OD): 6.96 (1H, d, J=1.5 Hz, H-2), 6.96 (1H, d, J=1.5 Hz, H-
2'), 6.85 (1H, d, J=1.3 Hz, H-4), 6.93 (1H, d, J=1.6 Hz, H-4'), 3.50 (1H, dd, J=14.5, 
5.0 Hz, H-8a), 3.77 (1H, dd, J=14.5, 4.4 Hz, H-8b), 3.33 (1H, dd, J=13.6, 4.5 Hz, H-
8'a), 3.64 (1H, dd, J=13.9, 3.2 Hz, H-8'b), 2.17 (1H, m, H-9), 2.27 (1H, m, H-9'), 3.83 
(1H, d, J=7.3 Hz, H-10), 2.48 (1H, ddd, J=16.7, 7.9, 2.3 Hz, H-10'a), 2.78 (1H, ddd, 
J=16.7, 5.7, 1.5 Hz, H-10'b) and 6.79 (1H, br s, H-15). 13C-NMR (125 MHz, CD3OD): 
163.2 (C, C-6), 162.9 (C, C-6'), 149.1 (C, C-13), 149.0 (C, C-13'), 127.6 (C, C-11), 
127.3 (C, C-5), 127.2 (C, C-5'), 123.2 (CH, C-2), 123.1 (CH, C-2'), 122.9 (C, C-11'), 
119.1 (C, C-15'), 114.3 (CH, C-4), 113.7 (CH, C-4'), 113.0 (CH, C-15), 97.7 (C, C-3), 
97.5 (C, C-3'), 43.9 (CH, C-9), 42.7 (CH2, C-8'), 40.1 (CH2, C-8), 37.1 (CH, C-9'), 
33.2 (CH, C-10) and 23.6 (CH2, C-10'). ESI-MS: m/z 618, 620 and 622 [M, 1:2:1] for 
C22H2479Br2N10O2. 
3.1.12 3,4-Dibromo-1H-pyrrole-2-carbamide (12) [24] 
White amorphous powder. 
UV (MeOH) Ȝmax: 234.0 and 276.2 nm. 
1H-NMR (500 MHz, DMSO-d6): 12.62 (1H, br s, -NH-1), 6.90 (1H, d, J=2.5 Hz, H-5) 
and 7.58 & 7.17 (2H, br s, -NH2). ESI-MS: m/z 266, 268 and 270 [M, 1:2:1] for 
C5H479Br2N2O. 
 
3.1.13 Aldisine (13) [25] 
Yellow residue. 
UV (MeOH) Ȝmax: 220.5, 250.4 and 303.9 nm. 
> @20DD
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1H-NMR (500 MHz, DMSO-d6): 12.13 (1H, br s, -NH-1), 6.97 (1H, d, J=2.5 Hz, H-2), 
6.53 (1H, d, J=2.5 Hz, H-3), 2.69 (2H, m, H-5), 3.34 (2H, m, H-6) and 8.30 (1H, br s, 
-NH-7). 13C-NMR (125 MHz, DMSO-d6): 194.3 (C, C-4), 162.2 (C, C-8), 127.9 (C, C-
8a), 123.5 (C, C-3a), 122.3 (CH, C-2), 109.5 (CH, C-3), 43.5 (CH2, C-6) and 36.5 
(CH2, C-5). EI-MS: m/z 164 (M) for C8H8N2O2. 
 
3.1.14 2-Bromoaldisine (14) [25] 
Yellow amorphous powder. 
890H2+Ȝmax: 233.9 and 311.1 nm. 
1H-NMR (500 MHz, DMSO-d6): 12.95 (1H, br s, -NH-1), 6.55 (1H, s, H-3), 2.69 (2H, 
m, H-5), 3.33 (2H, m, H-6) and 8.37 (1H, br s, -NH-7). 13C-NMR (125 MHz, DMSO-
d6): 193.5 (C, C-4), 161.3 (C, C-8), 129.4 (C, C-8a), 124.6 (C, C-3a), 111.2 (CH, C-
3), 105.2 (C, C-2), 43.4 (CH2, C-6) and 36.3 (CH2, C-5). EI-MS: m/z 242 and 244 (M, 
1:1) for C8H779BrN2O2. 
 
3.1.15 4-Bromo-1H-pyrrole-2-carbamide (15) [26-28] 
Yellow residue. 
890H2+Ȝmax: 232.9 and 269.9 nm. 
1H-NMR [500 MHz, (CD3)2CO)]: 10.90 (1H, br s, -NH-1), 6.84 (1H, dd, J=2.8, 1.5 Hz, 
H-3), 7.01 (1H, dd, J=2.5, 1.5 Hz, H-5) and 6.43 & 7.14 (2H, br s, -NH2). 13C-NMR 
(125 MHz, DMSO-d6): 161.1 (C=O), 126.9 (C, C-2), 121.2 (CH, C-5), 112.0 (CH, C-
3) and 94.8 (C, C-4). EI-MS: m/z 188 and 190 (M, 1:1) for C5H579BrN2O. 
 
3.2 Protein kinase inhibition 
 
Protein kinases are sensitive targets for various pharmacological purposes, e.g. 
VEGFR-2 is an important target in cancer therapy. This kinase was inhibited by 
distinct brominated pyrrole derivatives from S. carteri: Z-spongiacidin D (7), Z-
hymenialdisine (8), Z-3-bromohymenialdisine (9) as well as E-
debromohymenialdisine (6) and 3,4-dibromo-1H-pyrrole-2-carbamide (12). Z-
spongiacidin D (7) was shown to be the most active compound. It also inhibited 
AKT1, ARK5, AURORA-A, B-RAF-VE, CDK2/CycA, CDK4/CycD1, FAK, IGF1-R, 
SRC, VEGFR-2, COT, PLK-1, SAK and PDGFR-beta. A similar activity profile 
showed by Z-3-bromohymenialdisine (9), which inhibited AURORA-A, AURORA-B, 
CDK4/CycD1, FAK, SRC, VEGFR-2, COT, PLK1, SAK and PDGFR-beta. While, Z-
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hymenialdisine (8) was able to inhibit the activity of AKT1, ARK5, CDK2-CycA, 
CDK4/CycD1, FAK, VEGFR-2, COT, PLK1, SAK and PDGFR-beta. But, (-) 
clathramide C (1), agelongine (2) (+) manzacidin A (3), E-Debromohymenialdisine 
(6) and 3,4-dibromo-1H-pyrrole-2-carbamide (12) showed only a slight protein kinase 
inhibition. Finally, all other compounds were not active. The protein kinase inhibitory 
profiles of the selected compounds are summarized in Table 1.  
 
3.3 Cytotoxicity activity 
 
All compounds were subjected to determine their in-vitro cytotoxicity employing 
L5178Y and HCT116 cell lines. 
In the L5178Y cell lines, (+) dibromophakelline (5) and Z-3-bromohymenialdisine 
(9) showed cytotoxic activities with inhibition of growth 57.0% and 60.5%, 
respectively (10 µg/mL). While, the cytotoxicity of (-) clathramide C (1), Z-
spongiacidin D (7), Z-hymenialdisine (8) and 3,4-dibromo-1H-pyrrole-2-carbamide 
(12), was not as prominent (growth inhibition of 25.3%, 36.7%, 37.0% and 38.4%, 
respectively). But, agelongine (2), (+) manzacidin A (3), (-) 3-bromomanzacidin D (4), 
E-debromohymenialdisine (6), 2-debromostevensine (10), (±) ageliferin (11), aldisine 
(13), 2-bromoaldisine (14) and 4-bromo-1H-pyrrole-2-carbamide (15) showed no 
significant cytotoxic activity in this cell lines. The results were demonstrated in Figure 
2.  
The cytotoxic activities were further analysed on HCT116 cell lines. In 
accordance with the results, which obtained in L5178Y cell lines, Z-3-
bromohymenialdisine (9) and Z-hymenialdisine (8) exerted relatively high toxicity 
(significant effects at 25 µM after 24 h), but the other alkaloids, e.g. (+) 
dibromophakelline (5) showed no toxic effects. A relatively high toxicity was also 
caused by (±) ageliferin (11) and to a lesser extent, by E-debromohymenialdisine (7). 
All other compounds analyzed showed no significant cytotoxic effect up to 
concentrations of 50 µM. The results were illustrated in Figure 3. 
 
4 Discussion 
 
Marine sponges are of great pharmacological interest due to the diversity of their 
secondary metabolites. Although, the molecular mode of action of the most 
metabolites is still unclear, for a substantial number of compounds the mechanisms 
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by which they interfere with the pathogenesis of a wide range of diseases has been 
reported. Distinct metabolites possess antiviral, antitumor, anti-inflammatory, anti-
oxidative, antibiotic or immunosuppressive activity. Due to these important biological 
activities, sponges have the potential to provide future drugs against diseases like 
cancer, malaria and inflammatory diseases [2,29].  
This study was performed for the first time on the inhibitory effects of the 
compounds using 21 important protein kinases in-vitro. Despite the molecular 
similarity of distinct compounds (only marginal changes in structure), the effects of 
the compounds on protein kinase inhibition remained to be strongly dependent on 
the distinct structure. Z-spongiacidin D (7) exhibited the highest capacity to inhibit 
protein kinases. A potent inhibition of ARK5, CDK2/CycA, CDK4/CycD1, VEGFR-2, 
SAK and PDGFR-beta was detectable by Z-spongiacidin D (7). The structurally 
related, dibromonated compound Z-3-bromohymenialdisine (9) was also very potent, 
but with a slight different inhibition pattern of compound Z-spongiacidin D (7). The 
dibrominated compound Z-3-bromohymenialdisine (9), no inhibition of AKT1, ARK5, 
B-RAF-VE, CDK2/CycA and IGF1-R was detectable, but in case of AURORA-A and 
FAK a higher inhibitory effect was seen. The compounds Z-hymenialdisine (8) and 
E-debromohymenialdisine (6) were structurally similar to the previously mentioned 
compounds, but less potent. Since, E-debromohymenialdisine (6) is a non-
brominated compound, but also possessed protein kinase inhibitory activity, it has to 
be concluded that this structural element is no necessity. 
Protein kinase inhibition by hymenialdisine was already reported [4], especially 
kinases of the cell cycle seems to be affected. Also, it interacted with CDC2-Like 
Kinase 1 [30] and showed CHK1-modulatory effects of hymenialdisine analogues 
[31]. Moreover, it displayed an inhibition of checkpoint kinase by a hymenialdisine-
derived analogue [32]. This was congruent with our finding of the inhibition of 
CDK2/CycA and CDK4/CycD1.  
The effect of hymenialdisine/hymenialdisine analogues on 60 recombinant 
kinases was investigated systematically [33]. They reported eleven new targets like 
p90RSK, KDR, c-Kit, Fes, MAPK1, PAK2, PDK1, PKCT, PKD2, Rsk1 and SGK. 
They also reported these analogues enhanced and/or dramatically altered selectivity 
relative to hymenialdisine. This result was also congruent to our findings; Z-
spongiacidin D (7) and Z-3-bromohymenialdisine (9) showed a higher activity 
compared with Z-hymenialdisine (8). Our study reported an inhibition of ARK5 by Z-
hymenialdisine, as well as VEGFR-2 and a weaker effect of this compound to inhibit 
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AKT1, CDK2/CycA, CDK4/CycD1, FAK, COT, PLK1, SAK and PDGFR-beta. To the 
best of our knowledge, no report about e.g. inhibition of AURORA-A and AURORA-B 
by hymenialdisine/hymenialdisine analogues exists in the literature.  
This study was further performed to check the effect of protein kinases on the 
viability of tumor cells. In L5178Y cell lines, the potent compounds (+) 
dibromophakelline (5) and Z-3-bromohymenialdisine (9) showed a great inhibition of 
cell growth. While, Z-spongiacidin D (7), Z-hymenialdisine (8) and 3,4-Dibromo-1H-
pyrrole-2-carbamide (12) also showed a moderate inhibition of cell growth. While, the 
most of compounds were not or only marginaly toxic. The dibrominated compounds 
viz., (+) Dibromophakelline (5) and Z-3-bromohymenialdisine (9) showed a 
comparable high toxicity. While, the dibrominated compound (±) ageliferin (11) 
showed very weak toxicity. This indicates that no structural activity relationship 
between brome atoms in these alkaloids and cytotoxicity. 
On the other side, Z-hymenialdisine (8), Z-3-bromohymenialdisine (9) and (±) 
ageliferin (11) showed the highest cytotoxic effect on HCT116 cell lines. 
Consequently, this study demonstrated that the monobrominated compound Z-
hymenialdisine (8) and the dibrominated compound Z-3-bromohymenialdisine (9) 
had cytotoxic effects against both of these cell lines. To the best of our knowledge, 
no reported toxicity of ageliferin existed in the literature. No correlation could be 
drawn to the kinase inhibition experiments and the assays concerning cytotoxicity. 
 
5 Conclusion 
 
Fifteen compounds, mostly monobrominated pyrrole alkaloids were isolated from S. 
carteri had protein kinase inhibitory activity and cytotoxicity. The most potent 
compounds were Z-spongiacidin D (7), Z-hymenialdisine (8) and Z-3-
bromohymenialdisine (9). From the results of protein kinase inhibition and 
cytotoxicity displayed a good correlation, as distinct brominated pyrrole alkaloids 
effectively inhibited distinct protein kinases followed by a toxic mode of action. These 
compounds may be interesting for a potential use as pharmacological drugs. In 
conclusion, distinct pyrrole alkaloids isolated from S. carteri effectively inhibited 
distinct protein kinases in-vitro suggesting a potential use as pharmacological drugs. 
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Scheme 1a. Extraction and fractionation of the total methanol extract of S. carteri  sponge. 
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Scheme 1b. Chromatographic fractionation of n-butanol fraction of S. carteri  sponge. 
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Scheme 1c. Chromatographic fractionation of EtOAc fraction of S. carteri  sponge. 
The chromatographic techniques abbreviations in the three schemes: 
*A: Column chromatography on sephadex LH-20 using MeOH as mobile phase.  
*B: Column chromatography on RP-18 using acetonitrile as a mobile phase.  
*C: MPLC on RP-18 using H2O/MeOH gradient elution.  
*D: Precipitation by time. 
*E: Column chromatography on RP-18 using acetonitrile/H2O (3:7) as a mobile phase.  
*F: Semi-preparative HPLC on RP-18 using nanopure H2O/MeOH gradient elution. 
*G: MPLC on RP-18 using H2O/MeOH (7.5:2.5) as a mobile phase. 
*H: VLC on silica gel, using gradient elution consisting of different portions of n-
Hexane/CH2Cl2 to CH2Cl2/MeOH. 
*I: Column chromatography on Silica gel using CH2Cl2/MeOH gradient elution. 
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Figure 1: Chemical structures of the isolated compounds from S. carteri sponge. 
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Figure 2: Cytotoxicity of the isolated compounds in L5178Y lymphoma cells from S. carteri  sponge. 
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Figure 3: Cytotoxicity of the isolated compounds in HCT116 colon carcinoma cells from S. 
carteri  sponge. 
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Table 1. Inhibition of protein kinase activity of the isolated compounds from S. carteri  sponge. 
  
++: Residual kinase activity > 20 % DQG+: Residual kinase actiYLW\!DQG -: Residual kinase activity > 80 %. 
Activity on various protein kinases based on IC50 (µg/mL), Compound tested (concentration: 1 µg/mL). 
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(-) Clathramide C (1) - - ++ + - - - - - - - - - - - - - - - - - 
Agelongine (2) + - - - - - - - - - - - - - - - - - - - - 
(+) Manzacidin A (3) + - - - - - - - - - - - - - - - - - - - - 
E-Debromohymenialdisine (6) - + - - - + + - - - - - - - + - + + - - + 
Z-Spongiacidin D (7) + ++ + - + ++ ++ - - - - + + + ++ + + ++ - - ++ 
Z-Hymenialdisine (8) + ++ - - - + + - - - - + - - ++ + + + - - + 
Z-3-Bromohymenialdisine (9) - - ++ + - - ++ - - - - ++ - + ++ + + ++ - - ++ 
3,4-Dibromo-1H-pyrrole-2-
carbamide (12) - - - + - - - - + - - + + + + - - - - - - 
